NEW YORK, Feb. 6--Cetek Corporation will collaborate with Tularik in a project to develop assays and discover lead compounds, the company said today.
The partnership will apply Cetek's CE Assay, a capillary electrophoresis system to rank small molecule affinity for therapeutic target proteins, to develop lead compounds.
The companies did not reveal financial details nor discuss the therapeutic area for this collaboration.
Tularik is a publicly owned drug development company with research programs in cancer, viral disease, immune disorders, inflammation, obesity, diabetes and lipid disorders.
Cetek, based in Marlborough, Mass., is privately held. Its CE Assay system is the basis of a range collaborations with pharmaceutical and biotech firms.